to-BBB Announces Successful €10 Million Financing

Round C financing of €10 million with new and existing investors

02-Jul-2014 - Netherlands

to-BBB announced the successful finalization of a round C financing of €10 million with new and existing investors. The company also announced the appointment of Dr. Pericles (Perry) Calias as Senior Vice President Translational Medicine and the appointment of Leonard Kruimer as interim CEO to replace Willem van Weperen, who accepted a career opportunity outside the company.

Appointment Dr. Pericles Calias

Dr. Pericles Calias has recently joined to-BBB as Senior Vice President Translational Medicine. As such, he will be responsible for expanding and accelerating the development of our pre-clinical portfolio. Dr. Calias will coordinate the early regulatory, non-clinical, manufacturing and quality efforts as to-BBB continues its clinical development programs.  

Prior to joining to-BBB, Pericles Calias led the development of the CNS protein replacement programs at Shire. During his seven-year tenure there, he authored over 20 patents and held various leadership roles throughout the research and development organization. He also led the research efforts for several US and EU regulatory filings for various marketed products. Prior to Shire, Dr. Calias was part of the founding teams for two ocular companies, Eyetech and Eyegate Pharmaceutical. He will be based in Boston, where he will further strengthen to-BBB’s US presence.

Willem van Weperen comments on his stepping down: “The company is now well positioned to execute our clinical development strategy. At this point in time, I have chosen to embark on a new career opportunity and have decided to step down as CEO. I am proud to have positioned the company to the point where we have multiple compounds in clinical development. Furthermore, I am confident that the current management of to-BBB will be successful in bringing new treatments for severe brain diseases towards commercialization.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances